Literature DB >> 20809053

Cost of walking, exertional dyspnoea and fatigue in individuals with multiple sclerosis not requiring assistive devices.

Marco Franceschini1, Anais Rampello, Federica Bovolenta, Marino Aiello, Panagiota Tzani, Alfredo Chetta.   

Abstract

OBJECTIVE: To assess the cost of walking in individuals with multiple sclerosis and to investigate its relationship with dyspnoea and fatigue.
METHODS: In 46 individuals with multiple sclerosis and in 36 healthy controls, the cost of walking was measured during the 6-min walk test. Perceived breathlessness after walking was rated on a visual analogue scale and corrected for the distance walked. The subjects' perceived effect of fatigue was assessed by means of the Modified Fatigue Impact Scale.
RESULTS: The cost of walking was significantly higher in individuals with multiple sclerosis than in controls; however, individuals with multiple sclerosis with normal walking speeds had normal costs of walking. The cost of walking was directly related to the degree of disability, but not to breathlessness perception and fatigue. Individuals with an Expanded Disability Status Scale score greater than 2.5 were highly likely to show an increased cost of walking. Breathlessness perception was higher than in controls and was related to fatigue.
CONCLUSION: Individuals with multiple sclerosis, even with mild disability and not requiring any assistive devices, may have an increase in cost of walking. This suggests that an aerobic training programme should be considered in these patients. Energy expenditure when walking is not a determinant of fatigue or exertional dyspnoea in individuals with multiple sclerosis and low levels of disability.

Entities:  

Mesh:

Year:  2010        PMID: 20809053     DOI: 10.2340/16501977-0600

Source DB:  PubMed          Journal:  J Rehabil Med        ISSN: 1650-1977            Impact factor:   2.912


  8 in total

1.  Serum Compounds of Energy Metabolism Impairment Are Related to Disability, Disease Course and Neuroimaging in Multiple Sclerosis.

Authors:  Giacomo Lazzarino; Angela M Amorini; Axel Petzold; Claudio Gasperini; Serena Ruggieri; Maria Esmeralda Quartuccio; Giuseppe Lazzarino; Enrico Di Stasio; Barbara Tavazzi
Journal:  Mol Neurobiol       Date:  2016-11-08       Impact factor: 5.590

Review 2.  Comfortable walking speed and energy cost of locomotion in patients with multiple sclerosis.

Authors:  Alex Buoite Stella; Maria Elisa Morelli; Fabiola Giudici; Arianna Sartori; Paolo Manganotti; Pietro Enrico di Prampero
Journal:  Eur J Appl Physiol       Date:  2020-01-09       Impact factor: 3.078

3.  Gait abnormalities in multiple sclerosis: pathogenesis, evaluation, and advances in treatment.

Authors:  Michelle H Cameron; Joanne M Wagner
Journal:  Curr Neurol Neurosci Rep       Date:  2011-10       Impact factor: 5.081

4.  Oxygen Cost of Walking in People With Multiple Sclerosis and Its Association With Fatigue: A Systematic Review and Meta-analysis.

Authors:  Scott Rooney; Gavin McWilliam; Leslie Wood; Fiona Moffat; Lorna Paul
Journal:  Int J MS Care       Date:  2021-07-09

5.  The Submaximal Clinical Exercise Tolerance Test (SXTT) to Establish Safe Exercise Prescription Parameters for Patients with Chronic Disease and Disability.

Authors:  Eduard Gappmaier
Journal:  Cardiopulm Phys Ther J       Date:  2012-06

6.  Body composition in multiple sclerosis.

Authors:  Y Dionyssiotis
Journal:  Hippokratia       Date:  2013-01       Impact factor: 0.471

7.  Serum metabolic profile in multiple sclerosis patients.

Authors:  Barbara Tavazzi; Anna Paola Batocchi; Angela Maria Amorini; Viviana Nociti; Serafina D'Urso; Salvatore Longo; Stefano Gullotta; Marika Picardi; Giuseppe Lazzarino
Journal:  Mult Scler Int       Date:  2011-06-28

8.  The Relationship Between Walking Speed and the Energetic Cost of Walking in Persons With Multiple Sclerosis and Healthy Controls: A Systematic Review.

Authors:  Kyra Theunissen; Guy Plasqui; Annelies Boonen; Bente Brauwers; Annick Timmermans; Pieter Meyns; Kenneth Meijer; Peter Feys
Journal:  Neurorehabil Neural Repair       Date:  2021-04-13       Impact factor: 3.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.